Quinolones target two essential bacterial type II toposiomerase enzymes, DNA gyrase and DNA topoisomerase IV. Single amino acid changes in the[q]{.ul}uinolone-[r]{.ul}esistance-[d]{.ul}etermining[r]{.ul}egion (QRDR) of GyrA can cause quinolone resistance in*Escherichia coli* (Hooper and Jacoby[@bib8]). In the course of isolating ciprofloxacin-resistant mutants from*E. coli* J53, a common laboratory strain (Yi*et al*.[@bib14]), a nonsense mutation was found unexpectedly at amino acid 83 in the QRDR region of GyrA in the J53 CipR27 strain. Despite the essentiality of gyrase, the growth curves of J53 and J53 CipR27 at 30°C, 37°C and 40°C showed no differences (data not shown), suggesting that J53 CipR27 contained a suppressor tRNA allowing translation of GyrA despite the stop codon at position 83. Thus, we sought to develop a simple method to detect this and other UAG suppressor mechanisms.

The widely used*E. coli* moderate-copy-number cloning vector pBR322 was chosen for this purpose. pBR322 is 4361 base pairs in length and harbors the origin of replication of plasmid pMB1, a close relative of the plasmid ColE1. It also contains the*bla* gene, encoding β-lactamase and conferring ampicillin resistance, and the*tet* gene, encoding the tetracycline resistance protein (Bolivar*et al*.[@bib2]). Our strategy was to create a UAG mutation in the*bla* gene preventing full translation of β-lactamase and ampicillin resistance, which could be restored upon plasmid introduction into strains with suppressor activity. A similar approach cloning a nonsense codon within the chloramphenicol acetyltransferase (*cat*) gene in*E. coli* has been used in the past to prove the functionality of suppressors in mammalian cells (Capone*et al*.[@bib3]), but the detection of naturally occurring nonsense suppressors was not demonstrated.

Site-directed mutagenesis was performed in the*bla* gene of pBR322 by using a Phusion site-directed mutagenesis kit (Thermo Scientific, MA, USA) to substitute a codon for serine at amino acid 220 for an TAG stop codon (TCG→TAG change at 662 bp). The forward primer, which included the desired mutation (shown in bold underline) Amber-F2 5^′^-GACCACTTCTGCGCT**[A]{.ul}**GGCCCTTCCGGCTG-3^′^, Amber-R2, 5^′^-CTGCAACTTTATCCGCCTCCATCCAGTCTA-3^′^ and 10 ng of pBR322 template (New England Biolabs), was used in a final volume of 50 μl with the following PCR conditions: 98°C 30 s; 24 cycles of 98°C 10 s, 65°C for 30 s, 72°C for 4 min and a final elongation step of 72°C for 5 min. After gel purification, amplified DNA was ligated using T4 DNA Ligase in a 5-min reaction. A portion of 1 μl of the ligated product was used to transform 20 μl of MAX Efficiency^®^ DH5α Competent Cells (Invitrogen) and spread on tetracyline (10 μg/ml) LB plates for further selection. The mutated plasmid was verified by sequencing, using the primers bla-PCR-F (5^′^-AGTATTCAACATTTCCGTGTCG-3^′^) and bla-PCR-R (5^′^-TGCTTAATCAGTGAGGCACCTA-3^′^), and introduced into*E. coli* J53, J53 CipR27, DH5α (Grant*et al*.[@bib7]), BL21 (DE3) (commercial) and MG1655, which is a wild-type K-12*E. coli* control strain (Blattner*et al*.[@bib1]), by electroporation for further testing of ampicillin resistance. A wild-type pBR322 was also electroporated into the same strains as a control. Ampicillin resistance was determined by agar dilution MIC on Mueller Hinton agar at 37°C with an inoculum of^∼^10^4^ CFUs and by disk diffusion following in both cases CLSI recommendations and resistance breakpoints (MIC≥32 μg/ml and zone diameter ≤13mm, respectively) (CLSI[@bib5]).

*Escherichia coli* BL21 (DE3) and MG1655, which are known to lack UAG suppressor activity (Nilsson and Rydén-Aulin[@bib9]; O\'Donoghue*et al*.[@bib10]; Singaravelan, Roshini and Munavar[@bib11]), exhibited an increase in ampicillin MIC with wild-type plasmid pBR322 but no increase with pBR322-Stop (Table[1](#tbl1){ref-type="table"}). In contrast, DH5α and J53 with and without the*gyrA* CipR27 TAG mutation exhibited similar increases in ampicillin MIC in the presence of each plasmid. DH5α has a known UAG suppressor, but J53 was not previously known to have suppressor activity; the viability of the J53*gyrA* CipR27 further validates suppressor activity in this strain background (Table[1](#tbl1){ref-type="table"}).

###### 

Phenotype of ampicillin resistance determined by disk diffusion method and MIC in the laboratory strains.

                           Disk diffusion[^a^](#TFN001){ref-type="table-fn"}   MIC[^b^](#TFN002){ref-type="table-fn"}
  ------------------------ --------------------------------------------------- ----------------------------------------
  BL21 (DE3)               20                                                  2
  BL21 (DE3) pBR322        \<6                                                 \>256
  BL21 (DE3) pBR322-Stop   21                                                  2
  MG1655                   20                                                  2
  MG1655 pBR322            \<6                                                 \>256
  MG1655 pBR322-Stop       20                                                  4
  DH5 α                    20                                                  2
  DH5 α pBR322             \<6                                                 \>256
  DH5 α pBR322-Stop        \<6                                                 \>256
  J53                      20                                                  4
  J53 pBR322               \<6                                                 \>256
  J53 pBR322-Stop          \<6                                                 \>256
  J53 CipR27               21                                                  0.5
  J53 CipR27 pBR322        \<6                                                 \>256
  J53 CipR27 pBR322-Stop   \<6                                                 \>256

A disk of ampicillin 10μg (Becton, Dickinson and Company) was used.

MIC was determined by agar dilution method (CLSI[@bib5]).

To determine if*bla* trancript levels were similar in pBR322 and pBR322-Stop, we designed*bla* gene primers (*bla* gene: RT-bla-F; CGCCGCATACACTATTCTCA, RT-bla-R, AGTAAGTTGGCCGCAGTGTT, extracted RNA and determined expression levels by RT-qPCR (Vinué*et al*.[@bib12]). Similar transcript levels were seen in all of the reference strain backgrounds (Table[2](#tbl2){ref-type="table"}). Thus, differences in plasmid-encoded ampicillin resistance among the strains tested could not be attributed to changes in transcript levels and thus appear to be related to changes in translation, as expected for translational suppressor activity.

###### 

Relative*bla* transcript levels of pBR322 and pBR322-Stop in different strains.

                           Mean fold change   
  ------------------------ ------------------ ---------
  BL21 (DE3) pBR322        1.000              \(0\)
  BL21 (DE3) pBR322-Stop   0.756              (0.130)
  MG1655 pBR322            1.000              \(0\)
  MG1655 pBR322-Stop       0.826              (0.040)
  DH5 α pBR322             1.000              \(0\)
  DH5 α pBR322-Stop        0.807              (0.165)
  J53 pBR322               1.000              \(0\)
  J53 pBR322-Stop          0.678              (0.094)
  J53 CipR27 pBR322        1.000              \(0\)
  J53 CipR27 pBR322-Stop   0.689              (0.081)

SEM: error standard of the mean.

Although a*gyrA* Ser83stop mutation in*E. coli* J53 has been reported (Cesaro*et al*.[@bib4]), suppressor activity was not otherwise documented. To determine if suppressor activity occurs in*E. coli* clinical isolates, we obtained 22 sequential clinical urine*E. coli* strains each from a different patient from the Massachusetts General Hospital Clinical Microbiology laboratory that were selected for susceptibility to ampicillin and tetracycline to allow ampicillin susceptibility testing using pBR322 and pBR322-Stop. These plasmids were introduced individually by electroporation into each strain, and plasmid-free and plasmid-containing strains were compared ampicillin MICs and disk diameters (Table[3](#tbl3){ref-type="table"}). Although all strains tested showed a similar increase in MIC of ampicillin with introduction of pBR322 as seen in the reference strains, none showed a similar increase in ampicillin MIC with introduction of pBR322-Stop, indicating the absence of strong suppressor activity. Lower increases in ampicillin MIC of 4- to 64-fold, however, were seen in the presence of pBR322-Stop in all 22 strains, suggesting common but weak suppressor activity in clinical isolates. To our knowledge, suppressor activity has not been reported before in clinical isolates. UAG suppressor tRNAs vary greatly in their translational efficiency. Because all UAG suppressor tRNAs share the same codon--anticodon pairing, the differences must reside in other parts of the tRNA structure. Weak suppressors require changes at the first position of the anticodon (cardinal position) whereas strong suppressors have changes at the two other anticodon positions. Only when the cardinal nucleotide is embedded in a suitable extended anticodon and further embedded in an otherwise normal tRNA molecule, the anticodon performs as an efficient and accurate translational device (Yarus[@bib13]). This occurrence could explain the weak suppressor activity found in the clinical isolates. Alternatively, several genes known as antisuppressors have been found to cause reduction in suppressor activity and affect mainly nucleotide modification enzymes involved in tRNA maturation and ribosomal proteins (Eggertsson and Söll[@bib6]). Further studies are needed to elucidate the emergence of mutations in the tRNA and the presence of suppressors that could emerge and create low levels of resistance in a clinical setting.

###### 

Effects of pBR322 and pBR322-Stop on ampicillin resistance in a set of ampicillin- and tetracycline-susceptible*E. coli* clinical isolates.

       No plasmid   pBR322   pBR322-Stop                
  ---- ------------ -------- ------------- ------- ---- -----
  1    18           4        \<6           \>256   13   32
  2    20           8        \<6           \>256   12   64
  3    20           4        \<6           \>256   13   32
  4    20           4        \<6           \>256   13   32
  5    20           4        \<6           \>256   12   32
  6    27           4        \<6           \>256   14   64
  7    21           4        \<6           \>256   16   16
  8    20           4        \<6           \>256   14   32
  9    20           4        \<6           \>256   12   32
  10   21           4        \<6           \>256   17   16
  11   21           4        \<6           \>256   18   16
  13   19           4        \<6           \>256   15   16
  14   20           4        \<6           \>256   17   16
  15   21           2        \<6           \>256   16   32
  16   22           2        \<6           \>256   11   128
  17   20           4        \<6           \>256   14   32
  18   26           2        \<6           \>256   15   32
  19   21           4        \<6           \>256   15   32
  20   21           4        \<6           \>256   12   64
  21   20           4        13            128     17   16
  22   20           8        \<6           \>256   15   32
  23   21           2        \<6           \>256   16   16

A disk of ampicillin 10 μg (Becton, Dickinson and Company) was used.

MIC was determined by agar dilution method (CLSI[@bib5]).

This simple technique could be used to detect low to high levels of suppressor activity that could explain viability and widespread dissemination of resistance isolates.
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